NASDAQ:MRUSMerus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Merus NV Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.99 -0.19 (-1.44 %) (As of 08/11/2020 04:00 PM ET) Add Compare Share Today's Range$12.86Now: $12.99▼$13.3550-Day Range$13.23MA: $14.58▼$16.6552-Week Range$10.19Now: $12.99▼$20.95Volume43,294 shsAverage Volume107,315 shsMarket Capitalization$377.26 millionP/E RatioN/ADividend YieldN/ABeta0.66 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.67, Merus has a potential upside of 59.1% from its current price of $12.99.Amount of Analyst CoverageMerus has only been the subject of 3 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesMerus has received 269 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMerus has received 269 “underperform” votes. (Add your “underperform” vote.)Community SentimentMerus has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote “Outperform” if you believe MRUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merus insiders have bought 383,120.27% more of their company's stock than they have sold. Specifically, they have bought $21,801,401.00 in company stock and sold $5,689.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Merus is held by insiders.Percentage Held by Institutions62.00% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($2.29) to ($2.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.97 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRUS Previous Symbol CUSIPN/A CIK1651311 Webwww.merus.nl Phone31-0-30-253-8800Debt Debt-to-Equity RatioN/A Current Ratio5.52 Quick Ratio5.52Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.13 million Price / Sales12.12 Cash FlowN/A Price / Cash FlowN/A Book Value$5.61 per share Price / Book2.32Profitability EPS (Most Recent Fiscal Year)($2.33) Net Income$-55,150,000.00 Net Margins-243.85% Return on Equity-66.84% Return on Assets-30.30%Miscellaneous Employees98 Outstanding Shares29,042,000Market Cap$377.26 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $12.99 -0.19 (-1.44 %) (As of 08/11/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MRUS News and Ratings via Email Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Merus (NASDAQ:MRUS) Frequently Asked Questions How has Merus' stock been impacted by COVID-19 (Coronavirus)? Merus' stock was trading at $14.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRUS shares have decreased by 10.7% and is now trading at $12.99. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Merus? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merus. When is Merus' next earnings date? Merus is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Merus. What price target have analysts set for MRUS? 3 equities research analysts have issued 12 month target prices for Merus' stock. Their forecasts range from $16.00 to $23.00. On average, they anticipate Merus' stock price to reach $20.67 in the next year. This suggests a possible upside of 59.1% from the stock's current price. View analysts' price targets for Merus. Has Merus been receiving favorable news coverage? News coverage about MRUS stock has been trending somewhat positive recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merus earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Merus. Are investors shorting Merus? Merus saw a decline in short interest in February. As of February 15th, there was short interest totaling 311,000 shares, a decline of 15.6% from the January 31st total of 368,500 shares. Based on an average daily volume of 80,800 shares, the short-interest ratio is currently 3.8 days. Currently, 1.5% of the company's stock are short sold. View Merus' Short Interest. Who are some of Merus' key competitors? Some companies that are related to Merus include Seres Therapeutics (MCRB), ALX Oncology (ALXO), Myovant Sciences (MYOV), Dicerna Pharmaceuticals (DRNA), MacroGenics (MGNX), Rocket Pharmaceuticals (RCKT), Heron Therapeutics (HRTX), Portola Pharmaceuticals (PTLA), ZEALAND PHARMA/S (ZEAL), Akebia Therapeutics (AKBA), Innoviva (INVA), Zymeworks (ZYME), Zogenix (ZGNX), Amneal Pharmaceuticals (AMRX) and Odonate Therapeutics (ODT). View all competitors. What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Fulcrum Therapeutics (FULC), Opko Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Crispr Therapeutics (CRSP), Exelixis (EXEL) and ImmunoGen (IMGN). Who are Merus' key executives? Merus' management team includes the following people: Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific AdvisorMs. Jillian Connell, VP of Investor Relations & Corp. CommunicationsMr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52) When did Merus IPO? (MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. What is Merus' stock symbol? Merus trades on the NASDAQ under the ticker symbol "MRUS." Who are Merus' major shareholders? Merus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Platinum Investment Management Ltd. (0.66%), Alps Advisors Inc. (0.14%) and Swiss National Bank (0.12%). Company insiders that own Merus stock include Bvf Partners L P/Il, Mark Throsby and Value Fund L P Biotechnology. View institutional ownership trends for Merus. Which major investors are selling Merus stock? MRUS stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., and Alps Advisors Inc.. View insider buying and selling activity for Merus. Which major investors are buying Merus stock? MRUS stock was bought by a variety of institutional investors in the last quarter, including Swiss National Bank. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Merus. How do I buy shares of Merus? Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Merus' stock price today? One share of MRUS stock can currently be purchased for approximately $12.99. How big of a company is Merus? Merus has a market capitalization of $377.26 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe. What is Merus' official website? The official website for Merus is www.merus.nl. How can I contact Merus? Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
